• Bookmark this Page
  • Print this Page

News Room

Teva’s Azilect Unlikely to See Additional Utility in Early Parkinson’s Based on Recent Trial Results

April 2, 2013

 Financial Times (FT.com)
April 2, 2013
Teva’s Azilect Unlikely to See Additional Utility in Early Parkinson’s Based on Recent Trial Results

Featurng: Dr. Andrew Feigin, investigator at the Feinstein Institute for Medical Research
 

Read this Story

Back to Top